1. Scrip
  2. >>New Products

Bristol’s Opdivo Joins Keytruda, Imfinzi In Perioperative NSCLC Treatment Space

 
• By Joseph Haas

PD-1 inhibitor Opdivo has obtained US FDA approval for pre- and post-surgical treatment in operable non-small cell lung cancer, but Merck and AstraZeneca got there first.

Bristol Myers Squibb office building in Brisbane, CA
BMS's Opdivo gets approval for perioperative therapy in resectable NSCLC • Source: Shutterstock

Bristol Myers Squibb Company has racked up another indication for its anti-PD-1 blockbuster Opdivo (nivolumab), joining Merck & Co., Inc.’s PD-1 inhibitor, Keytruda (pembrolizumab), and AstraZeneca PLC’s PD-L1 inhibitor, Imfinzi (durvalumab), with an approval for perioperative combination therapy in resectable non-small cell lung cancer on 4 October.

Key Takeaways

  • BMS gets approval for Opdivo in perioperative resectable non-small cell lung cancer, joining Merck’s Keytruda and AstraZeneca’s Imfinzi in that setting.

BMS obtained US Food and Drug Administration approval of Opdivo for presurgical treatment with platinum-doublet chemotherapy and post-surgical monotherapy in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

More from Scrip

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.